https://www.selleckchem.com/pr....oducts/sb290157-tfa.
Worldwide uptake of new drugs in the treatment of rifampicin-resistant tuberculosis (RR-T has been extremely low. In June 2018, ahead of the release of the updated WHO guidelines for the management of RR-TB, South Africa announced that bedaquiline (BDQ) would be provided to virtually all RR-TB patients on shorter or longer regimens. South Africa has been the global leader in accessing BDQ for patients with RR-TB, who now represent 60% of the global BDQ cohort. The use of BDQ within a shorter modified regimen has generated the pro
Like
Comment
Share
